Table 2.
Comorbidities and concomitant medications at baseline for 156 obese hypogonadal men with type 2 diabetes mellitus treated with testosterone undecanoate for up to 6 years.
| Comorbidities | |
| Hypertension | 153 (99.4%) |
| Type 2 diabetes | 156 (100%) |
| Dyslipidaemia | 156 (100%) |
| Coronary artery disease | 37 (23.7%) |
| Myocardial infarction | 19 (12.2%) |
| Concomitant medications for diabetes at baseline | |
| Metformin | 36 (23.1%) |
| Insulin | 25 (16%) |
| Sulfonylurea | 8 (5.1%) |
| Acarbose | 2 (1.3%) |
| Antidiabetic drugs not further specified | 51 (32.7%) |
| Total antidiabetic drugs | 122 (78.2%) |
| No diabetes drugs (including 2 patients who were “prescribed” a diet) |
29 (18.6%) |
| No information available | 9 (5.8%) |
| Other concomitant medication categories at baseline | |
| Antihypertensives | 123 (78.8%) |
| Lipid-lowering drugs | 99 (63.5%) |